Publications
RHU SPRINT scientists already have numerous publications to their credit in prestigious journals:
2000
Clonal T-cell receptor γ gene rearrangements in Sézary syndrome. Vergier B, et al. Blood. 2000;95:2212–2218. DOI: [https://doi.org/10.1182/blood.V95.7.2212]
2011
KIR3DL2 is a marker of malignant T cells in Sézary syndrome and mycosis fungoides. Bensussan A, Bagot M, Marie-Cardine A, et al. Journal of Investigative Dermatology. 2011;131:969–976. DOI: [https://doi.org/10.1038/jid.2010.413]
2014
KIR3DL2 is a therapeutic target in cutaneous T-cell lymphoma. Marie-Cardine A, et al. Cancer Research. 2014;74:6060–6070. DOI: [https://doi.org/10.1158/0008-5472.CAN-13-3777]
High-throughput sequencing of the T-cell receptor repertoire in cutaneous T-cell lymphoma. de Masson A, et al. Haematologica. 2014;99:527–534. DOI: [https://doi.org/10.3324/haematol.2013.094870]
Prognostic factors and clinical outcomes in Sézary syndrome. de Masson A, et al. Journal of the American Academy of Dermatology. 2014;71:926–934. DOI: [https://doi.org/10.1016/j.jaad.2014.06.018]
KIR3DL2 expression in cutaneous T-cell lymphomas. de Masson A, et al. British Journal of Dermatology. 2014;170:720–724. DOI: [https://doi.org/10.1111/bjd.12724]
2015
KIR3DL2 engagement triggers apoptosis of Sézary syndrome malignant T cells. Moins-Teisserenc H, et al. Journal of Investigative Dermatology. 2015;135:247–257. DOI: [https://doi.org/10.1038/jid.2014.363]
Alemtuzumab therapy in cutaneous T-cell lymphoma. Scarisbrick JJ, et al. Journal of Clinical Oncology. 2015;33:3766–3773. DOI: [https://doi.org/10.1200/JCO.2014.60.3969]
2017
Romidepsin for treatment of cutaneous T-cell lymphoma: long-term follow-up. Prince HM, et al. The Lancet. 2017;390:555–566. DOI: [https://doi.org/10.1016/S0140-6736(17)31599-8]
KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Battistella M, et al. Blood. 2017;130:2900–2902. DOI: [https://doi.org/10.1182/blood-2017-06-792382]
Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with Sézary syndrome. Hurabielle C, Thonnart N, Ram-Wolff C, et al. Clinical Cancer Research. 2017;23:3619–3627. DOI: [https://doi.org/10.1158/1078-0432.CCR-16-1732]
Gene expression profiling in Sézary syndrome identifies prognostic biomarkers. Laurent C, et al. Journal of Clinical Oncology. 2017;35:2008–2017. DOI: [https://doi.org/10.1200/JCO.2016.71.2740]
2018
High-throughput sequencing of the T-cell receptor β gene identifies aggressive early-stage mycosis fungoides. de Masson A, O’Malley JT, et al. Science Translational Medicine. 2018;10. DOI: [https://doi.org/10.1126/scitranslmed.aar5894]
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): a phase 3 trial. Kim YH, Bagot M, et al. The Lancet Oncology. 2018;19:1192–1204. DOI: [https://doi.org/10.1016/S1470-2045(18)30379-6]
2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody in relapsed or refractory cutaneous T-cell lymphoma: phase 1 trial. Bagot M, Porcu P, Marie-Cardine A, et al. The Lancet Oncology. 2019;20:1160–1170. DOI: [https://doi.org/10.1016/S1470-2045(19)30320-1]
KIR3DL2 expression in cutaneous T-cell lymphomas: diagnostic and therapeutic implications. Bonnet P, Moins-Teisserenc H, et al. British Journal of Dermatology. 2019;180:419–420. DOI: [https://doi.org/10.1111/bjd.17532]
EORTC recommendations for treatment of Sézary syndrome. Scarisbrick JJ, et al. British Journal of Dermatology. 2019;181:350–357. DOI: [https://doi.org/10.1111/bjd.17559]
2020
Clonal T-cell receptor sequencing identifies disease progression in cutaneous T-cell lymphoma. O’Malley JT, de Masson A, et al. Clinical Cancer Research. 2020;26:408–418. DOI: [https://doi.org/10.1158/1078-0432.CCR-19-1968]
Immune microenvironment in cutaneous T-cell lymphomas. Piquemal D, et al. Cancers. 2020;12:3204. DOI: [https://doi.org/10.3390/cancers12113204]
2021
Genetic alterations driving Sézary syndrome pathogenesis. Poglio S, et al. Leukemia. 2021;35:1696–1709. DOI: [https://doi.org/10.1038/s41375-020-01065-2]
2022
Single-cell and molecular analysis of Sézary syndrome identifies pathogenic T-cell subsets. de Masson A, et al. Blood. 2022;139:1820–1832. DOI: [https://doi.org/10.1182/blood.2021013417]
KIR3DL2 targeting induces antitumor activity in cutaneous T-cell lymphoma. Sonigo C, Marie-Cardine A, et al. Blood. 2022;139:2712–2716. DOI: [https://doi.org/10.1182/blood.2021013804]
Genomic landscape of Sézary syndrome. Vallet N, et al. Blood. 2022;140:2500–2513. DOI: [https://doi.org/10.1182/blood.2022016789]
2023
Genomic and transcriptomic landscape of Sézary syndrome. Menguy S, Pham-Ledard A, et al. Journal of Investigative Dermatology. 2023;143:124-133.e3. DOI: [https://doi.org/10.1016/j.jid.2022.08.026]
Single-cell analysis of malignant T cells in cutaneous T-cell lymphoma. Van Anh TA, Battistella M, et al. Journal of Investigative Dermatology. 2023. DOI: [https://doi.org/10.1016/j.jid.2023.01.027]
2024
Failure of second challenge with mogamulizumab in C-C chemokine receptor 4-positive cutaneous T-cell lymphoma. Stammler R, Ta VA, Cohen E, Ram-Wolff C, Bozonnat A, Battesti G, Louveau B, Mourah S, Battistella M, Moins-Teisserenc H, de Masson A. British Journal of Dermatology. 2024;190:920–921. DOI: [https://doi.org/10.1093/bjd/ljae085]
Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas. Giustiniani J, Ta VA, Belkhelouat S, Battistella M, Ouahbi D, Ram-Wolff C, Louveau B, Mourah S, Bagot M, Moins-Teisserenc H, Ortonne N, Bensussan A, de Masson A. Journal of Investigative Dermatology. 2024;144:2329–2332. DOI: [https://doi.org/10.1016/j.jid.2024.03.019]
Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study. Bozonnat A, Beylot-Barry M, Dereure O, D’Incan M, Quereux G, Guenova E, Perier-Muzet M, Dalle S, Grange F, Viguier MA, Ram-Wolff C, Feldmeyer L, Beltraminelli H, Bonnet N, Amatore F, Maubec E, Franck N, Machet L, Chasset F, Brunet-Possenti F, Bouaziz JD, Battistella M, Donzel M, Pham-Ledard A, Bejar C, Moins-Teisserenc H, Mourah S, Saiag P, Hainaut E, Michel C, Bens G, Adamski H, Aubin F, Boulinguez S, Joly P, Tedbirt B, Templier I, Troin L, Montaudié H, Ingen-Housz-Oro S, Faiz S, Mortier L, Dobos G, Bagot M, Resche-Rigon M, Montlahuc C, Serret-Larmande A, de Masson A. EClinicalMedicine. 2024;73:102679. DOI: [https://doi.org/10.1016/j.eclinm.2024.102679]
Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre. de Masson A, Lazaridou I, Moins-Teisserenc H, Ram-Wolff C, Giustiniani J, Bagot M, Battistella M, Bensussan A. Immunology Letters. 2024;268:106871. DOI: [https://doi.org/10.1016/j.imlet.2024.106871]
2025
Computational Free Flow Cytometry for Sézary Cells Identification and Quantification. Ta VA, Ram-Wolff C, Annabi E, Chauvel C, de Masson A, Beylot-Barry M, Soulier J, Bagot M, Vial JP, Veyrat-Masson R, Moins-Teisserenc H. Journal of Investigative Dermatology. 2025. DOI: [https://doi.org/10.1016/j.jid.2025.03.003]